drugset / Trial / NCT05727267
A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate
Phase 1
Completed
26 enrolled
University Medical Center Hamburg-Eppendorf
German Center for Infection Research · collabHelmholtz Zentrum München · collabInstitute of Virology Helmholtz Zentrum München (HMGU) · collabLMU Klinikum · collabThe Fraunhofer-Gesellschaft · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is an open-label, ascending dose phase 1a trial to assess the safety and immunogenicity of a heterologous protein prime/MVA boost therapeutic hepatitis B vaccine
Timeline
- Start
- 2024-01-23
- Primary completion
- 2026-05-21
- Completion
- 2026-05-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HEPLISAV-B | Vaccine | — | Intramuscular |
| Subject | TherVacB | Vaccine | — | Intramuscular |